" class="no-js "lang="en-US"> inHEART - Medtech Alert
Saturday, August 30, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
inHEART | Pharmtech Focus

inHEART

About inHEART

inHEART

At inHEART, we are committed to delivering the world’s most sophisticated, AI-enabled, digital twin of the heart to advance the care of patients living with cardiac disease.
‍
We believe all patients deserve access to world-class expertise that guides and optimizes treatment strategies to support improved clinical outcomes and return patients to full, healthy lives.

Related Story

Cardiovascular

 inHEART Receives FDA Clearance for Novel 3D Cardiac Modeling Solution | Pharmtech Focus

inHEART Receives FDA Clearance for Novel 3D Cardiac Modeling Solution

May 25 2022

inHEART, a privately-held medical device company delivering the world’s most sophisticated digital twin of the […]